<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635256</url>
  </required_header>
  <id_info>
    <org_study_id>ZKS-121-003</org_study_id>
    <nct_id>NCT02635256</nct_id>
  </id_info>
  <brief_title>Hypofractionated Radiosurgery for Localised Prostate Cancer</brief_title>
  <acronym>HYPOSTAT</acronym>
  <official_title>Hypofractionated Radiosurgery for Localised Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saphir Radiosurgery Center Northern Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypofractionated radiosurgery has been investigated in a few trials and appears to be safe
      and feasible.

      Investigators initiated this multicenter phase II prospective trial to analyse feasibility
      (toxicity) of hypofractionated radiosurgery with 5 fractions in patients with localised
      prostate cancer, who are ineligible for the &quot;PREFERE trial&quot; under the hypothesis that the
      ratio of patients with late toxicity ≥ grade 2 after 1 year amounts 2,8% and is significant
      lower than 17.5%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental radiosurgery of prostate with 5 fractions each with 7,00 Gy (total application
      rate of 35,00 Gy).

      Planned visits are: Baseline, visits at every radiation day and four follow ups (4-6 weeks, 3
      months, 6 months and one year after last day of radiation).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late toxicity measured with Radiation Therapy Oncology Group-(RTOG)-Score</measure>
    <time_frame>12-15 months after radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity analysed by Adverse Event (AE)- and Serious Adverse Event (SAE)-reports.</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen (PSA)</measure>
    <time_frame>At the time of inclusion and 1, 3, 6-9 and 12-15 months after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>Screening and 3, 6-9 and 12-15 months after radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC Quality of Life Questionnaire (QLQ) C30</measure>
    <time_frame>At the time of inclusion and 12-15 months after radiotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Hypofractionated Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 fractions with 7 Gy, total dose 35 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Radiosurgery</intervention_name>
    <description>Image-guided stereotactic Linac based RT preferable with &quot;dedicated radiosurgery system&quot; such as CyberKnife</description>
    <arm_group_label>Hypofractionated Radiosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Localised, histopathologically confirmed Prostate Cancer (cT1-3 N0 M0)

          -  Gleason-grade ≤7

          -  Guideline-based staging

          -  Age ≥ 60 years

          -  PSA &lt; 15 ng/ml

          -  Volume of the prostate &lt;80 cm³

          -  IPSS-Score ≤12

          -  Written informed consent

        Exclusion Criteria:

          -  History of prior pelvic radiotherapy

          -  Contraindication to MRI or Fiducial marker implantation (e.g. allergy to gold),

          -  Immunosuppressive therapy

          -  Relevant comorbidity thought to adversely affect treatment compliance,

          -  Legal incapacity or lack of informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Dunst, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juergen Dunst, Prof.</last_name>
    <phone>0049/431/500</phone>
    <phone_ext>26501</phone_ext>
    <email>Juergen.Dunst@uksh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oliver Blanck, Dr.</last_name>
    <phone>0049/3843/34599</phone>
    <phone_ext>0</phone_ext>
    <email>blanck@saphir-rc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saphir Radiosurgery Center Frankfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt, Department of Radiation Therapy and Oncology</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Keller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Panagiotis Balermpas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saphir Radiosurgery Center Northern Germany</name>
      <address>
        <city>Güstrow</city>
        <zip>18273</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Wurster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juergen Dunst, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Huber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rene Baumann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>European Cyberknife Center Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Muacevic, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristopf Fürweger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Juergen Dunst, Prof.</investigator_full_name>
    <investigator_title>Prof. Dr. med. Juergen Dunst</investigator_title>
  </responsible_party>
  <keyword>hypofractionation</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

